ijms-logo

Journal Browser

Journal Browser

Recent Advances in Immunotheragnostics: From Molecular Basis to Targeted Pharmaceutical Design 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 17961

Special Issue Editors


E-Mail Website
Guest Editor
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany
Interests: (radio)immunotherapy and imaging of tumors; bispecific antibodies; genetically modified immune effector cells; autoimmunity
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz Zentrum Dresden Rossendorf (HZDR), 01328 Dresden, Germany
Interests: chimeric antigen receptors; B cell maturation antigen; biological therapy; antibody engineering; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Within the last few decades, immunotherapy has gained an increasingly important role beyond standard therapies and is thus considered the fourth pillar of anticancer therapy. However, from a clinical perspective, not only an efficient treatment but also reasonable patient selection and therapy monitoring are highly required for improved patient outcomes. Recent advances in immunotheranostics can pave the way toward precision oncology and personalized medicine. The implementation of imaging tools before, during, or after immunotherapy, especially in the case of living drugs, can help to predict and understand possible effects, as well as side effects of immunotherapy. Further, they can prospectively allow therapeutic interventions if needed. Precise and periodic target verification and assessment of molecular response to therapy can help decision making and guide appropriate patient-specific treatment.

This Special Issue aims to provide a comprehensive overview of recent advances in cancer immunotheranostics and their significance for personalized medicine. Basic and translational original or review articles submitted to this issue may address various types of immunotherapeutics ranging from small molecules, peptides, nanoparticles, nanobodies, full-size, and recombinant antibodies to cells. Authors are encouraged to address topics including but not limited to biomedical research in the field of theranostic development, target and biomarker identification, novel targeted immunotheranostics, molecular in vivo imaging, or sophisticated combinatorial approaches for immunotherapy and tumor visualization.

Prof. Dr. Michael P. Bachmann
Dr. Anja Feldmann
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotheranostics
  • molecular imaging
  • radioimmunotherapy
  • cancer immunotherapy
  • targeted therapy
  • biochemical response
  • image-guided therapy
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 3719 KiB  
Article
Preclinical Characterization of the 177Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5
by Franziska Striese, Christin Neuber, Sandy Gräßel, Claudia Arndt, Martin Ullrich, Jörg Steinbach, Jens Pietzsch, Ralf Bergmann, Hans-Jürgen Pietzsch, Wiebke Sihver, Marcus Frenz, Anja Feldmann and Michael P. Bachmann
Int. J. Mol. Sci. 2023, 24(11), 9420; https://doi.org/10.3390/ijms24119420 - 29 May 2023
Cited by 4 | Viewed by 2113
Abstract
Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required. The membrane protein prostate stem cell antigen (PSCA) is highly overexpressed in most [...] Read more.
Prostate specific membrane antigen (PSMA) is an excellent target for imaging and treatment of prostate carcinoma (PCa). Unfortunately, not all PCa cells express PSMA. Therefore, alternative theranostic targets are required. The membrane protein prostate stem cell antigen (PSCA) is highly overexpressed in most primary prostate carcinoma (PCa) cells and in metastatic and hormone refractory tumor cells. Moreover, PSCA expression positively correlates with tumor progression. Therefore, it represents a potential alternative theranostic target suitable for imaging and/or radioimmunotherapy. In order to support this working hypothesis, we conjugated our previously described anti-PSCA monoclonal antibody (mAb) 7F5 with the bifunctional chelator CHX-A″-DTPA and subsequently radiolabeled it with the theranostic radionuclide 177Lu. The resulting radiolabeled mAb ([177Lu]Lu-CHX-A″-DTPA-7F5) was characterized both in vitro and in vivo. It showed a high radiochemical purity (>95%) and stability. The labelling did not affect its binding capability. Biodistribution studies showed a high specific tumor uptake compared to most non-targeted tissues in mice bearing PSCA-positive tumors. Accordingly, SPECT/CT images revealed a high tumor-to-background ratios from 16 h to 7 days after administration of [177Lu]Lu-CHX-A″-DTPA-7F5. Consequently, [177Lu]Lu-CHX-A″-DTPA-7F5 represents a promising candidate for imaging and in the future also for radioimmunotherapy. Full article
Show Figures

Figure 1

Review

Jump to: Research

23 pages, 970 KiB  
Review
Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus
by Daniele Accapezzato, Rosalba Caccavale, Maria Pia Paroli, Chiara Gioia, Bich Lien Nguyen, Luca Spadea and Marino Paroli
Int. J. Mol. Sci. 2023, 24(7), 6578; https://doi.org/10.3390/ijms24076578 - 31 Mar 2023
Cited by 32 | Viewed by 15507
Abstract
Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of [...] Read more.
Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease. Full article
Show Figures

Figure 1

Back to TopTop